Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Multiple therapeutic options may prevent apoptosis in the treatment of NASH (Table 17)
  • In one study of 247 nondiabetic adults, 43% of those receiving vitamin E experienced improvements in NASH vs placebo (19%; P = .001)[Sanyal 2010]
  • Results of large-scale, well-controlled trials are needed before they can be recommended for HIV-infected patients in the treatment of NASH

Action required

Keywords: Diabetes, Hepatic Complications, Insulin Resistance, Special Populations

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.